• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Arthritis News / Leflunomide and Pregnancy Outcomes Explored

Leflunomide and Pregnancy Outcomes Explored

May 24, 2010 By Arthritis Center

Interleukin-17

Leflunomide use during early pregnancy is associated with fetal malformations in animal studies and is classified as a pregnancy category X by the U.S. Food and Drug Administration.  However, little is known about pregnancy outcomes in humans exposed to leflunomide in early pregnancy, particularly in those who receive “wash-out” with cholestyramine (a drug sequestrant).   Here, Chambers et al (Arthritis Rheum 2010; 62(5):1494) present birth outcomes for the largest series of women exposed to leflunomide during early pregnancy.

Methods

Participants were women enrolled in the Organization of Teratology Information Specialists (OTIS) Collaborative Research Group.  Clinical data and birth outcomes for women with rheumatoid arthritis (RA) or juvenile rheumatoid arthritis (JRA) who took at least one dose of leflunomide after their estimated date of conception and were compared to disease-matched women unexposed to any teratogen during pregnancy and to a group of healthy-control pregnant women.  Cases were collected between 1999-2009.

Results

A total of 250 women were enrolled (64 in the leflunomide exposed group; 108 in the disease-matched group; and 78 in the healthy control group).  There were imbalances among the groups in baseline characteristics.  Compared to the healthy control group, leflunomide treated patients were of lower socioeconomic status, less likely to be on multivitamin or folate supplementation, and more likely to report tobacco use during pregnancy (25% vs. 10%; p<0.01).  The average gestational timing of leflunomide after conception was 3.1 weeks.  The longest exposure after conception was 8.6 weks.  Cholestyramine wash-out was performed in 61 leflunomide treated women (95%).  There was no significant difference between the groups in the proportion of liveborn or miscarried pregnancies.  Only one pregnancy to leflunomide exposed mother was electively terminated.  Among the live births, delivery by cesarean section was significantly more common among leflunomide exposed mothers (48%) compared to disease-matched non-exposed mothers (29%) or healthy control mothers (25%).  Preeclampsia was not significantly higher in leflunomide exposed mothers.

Major structural defects occurred in 3 of 63 leflunomide exposed women (5%), all in the liveborn offspring, compared to 7% in the disease-matched control group and 4% in the healthy control group.  These consisted of one occult spinal dysraphism, one uretero pelvic junction obstruction and multicystic kidney disease; and one microcephaly.  There was a trend to higher number of minor abnormalities in the offspring of leflunomide exposed women (i.e. the proportion with ≥ 3 minor abnormalities was 47, 32, and 29% for the leflunomide-exposed, disease-matched control, and healthy-control groups, respectively; p=0.10).

Compared to the control groups, gestational age was significantly lower in leflunomide exposed women, with significantly lower birthweight compared to disease-matched controls.  After adjusting for differences in maternal age, socioeconomic status, smoking, and preeclampsia, leflunomide was no longer significantly associated with lower gestational age or lower birth weight.

Among 19 leflunomide exposed women not-eligible for the cohort study, two malformations were encountered: aplasia cutis in the surviving member of a twin pair, and a birth resulting in multiple malformations in a mother treated with leflunomide for lupus.

Conclusions

Leflunomide exposure early in pregnancy was not associated with an increase in the number of major malformations, or adverse delivery outcomes compared to unexposed mothers with RA or JRA or healthy control mothers.  Lower gestational age and birth weight were explained not by leflunomide exposure itself, but to sociodemographic factors linked to leflunomide use in the cohort.

Editorial Comment

It is actually quite surprising and reassuring that major malformations were not higher than what was observed in this study.  This could indicate that leflunomide is not as teratogenic in humans as what was observed in animal studies, or that leflunomide washout with cholestyramine is very effective in limiting teratogenic effects.  These data are clinically applicable for counseling women who may have been exposure during early pregnancy, particularly regarding issues of elective termination.   Regardless, many practitioners will still choose not to use leflunomide in women of childbearing potential if there are other alternatives available.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Recent News

Exercise Tips for Arthritis Patients

How Does Exercise Affect my Joints? How Frequently Should I Be Exercising? Should I Lose Weight for Exercise to be

Risks and Benefits of Biologic Medications

Victoria Ruffing, RN, BC, Director of Patient Education at the Johns Hopkins Arthritis Center, shares the risks and benefits of biologic for

How to Manage Rheumatoid Arthritis Flares

Through research, doctors have a clearer understanding of how flares can impact a patient on a personal and emotional level. Dr. Uzma Haque

Complementary & Alternative Medicines for Psoriatic Arthritis

There are many complementary & alternative medicines and practices that have been found to be beneficial in curbing arthritis pain,

I can’t be a runner because I have Rheumatoid Arthritis (RA), right?

Dr. Manno discusses running and Rheumatoid Arthritis. Is it an option for the RA patient?

News Categories

  • Ankylosing Spondylitis News
  • Fibromyalgia News
  • Gout News
  • Lupus News
  • Osteoarthritis News
  • Osteoporosis News
  • Psoriatic Arthritis News
  • Rheumatoid Arthritis News
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy